Emerging realities of biotech-pharma deals shifts business strategy
Barbara Yanni, VP Licensing at Merck & Co., joins the Vaughn, along with VPs from AstraZeneca and Alnylam Pharmaceuticals.
He is simply "The Vaughn," a man who needs no further introduction for anyone cutting a deal in the heady mega "dollar world where
Big Pharma and Biotech meet" over half of the 2,250 delegates at BIO-Europe 2007 attending the panel discussion on "The Changing
World Order of Biotech-Pharma," had no trouble spotting the moderator Vaughn M. Kailian, General Partner of MPM Capital. Noting that
Abbott, Bristol-Myers Squibb and Wyeth have invested heavily building new biotech facilities ...
Pharma moving further upstream in the hunt for early-stage deals
Suddenly everything changed in 2006. Where pharmaceutical companies led the dance with the biotech sector with in-licensing and
merger and acquisitions focused on mid- to late-stage projects, sometime last year all that changed with an abrupt shift of focus
upstream toward early stage deals. During an intensive 90-minute Interactive Workshop at BIO-Europe 2007 panelists took on
"The Trend towards Early Stage M&A and Licensing - What are the New Rules to the Dating Game?" ...
MORE STORIES
A Day in the Life of Experienced Dealmakers
New Tipping Point in Pharma deals: Proof of Concept
Partners Required : No one goes it alone in "magic" US market
The EBD Group and Scrip launch Bio-Pharma Partnering magazine.
Delegates book an average of seven face-to-face meetings per day at an EBD partnering event. But are they any good at it?
Two business development experts offer some tips ...
The EBD Group and Scrip launch Bio-Pharma Partnering magazine.
